申请人:Lilly Industries Limited
公开号:US04448787A1
公开(公告)日:1984-05-15
Compounds are described of the formula ##STR1## in which R.sup.1 is COOR.sup.5, CONHR.sup.5, cyano, 5-tetrazolyl or R.sup.6, where R.sup.5 is hydrogen or C.sub.1-8 alkyl and R.sup.6 is phenyl or naphthyl, the phenyl or naphthyl group being optionally substituted by one or more group selected from halogen, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, hydroxy, benzyloxy, nitro, trifluoromethyl, carboxyl, C.sub.1-4 alkylsulphinyl, C.sub.1-4 alkylsulphonyl, N(R.sup.5).sub.2, NHCOR.sup.5 and SR.sup.5 ; R.sup.2 is R.sup.6 or --CH.dbd.CH--R.sup.6 when R.sup.1 is COOR.sup.5, CONHR.sup.5, cyano or 5-tetrazolyl, or R.sup.2 is --CH.dbd.CH--R.sup.6 when R.sup.1 is R.sup.6 ; R.sup.3 is hydrogen, C.sub.1-6 alkyl, halogen, hydroxy or --OCH.sub.2 R.sup.6 ; and R.sup.4 is hydrogen, C.sub.1-6 alkyl or halogen; and salts thereof. The compounds have pharmaceutical properties and in particular are useful in the treatment of immediate hypersensitivity conditions such as asthma.
该文描述了化合物的公式为##STR1##其中R.sup.1是COOR.sup.5,CONHR.sup.5,氰基,5-四唑基或R.sup.6,其中R.sup.5是氢或C.sub.1-8烷基,R.sup.6是苯基或萘基,苯基或萘基团可以选择性地由一个或多个从卤素,C.sub.1-6烷基,C.sub.1-4烷氧基,羟基,苄氧基,硝基,三氟甲基,羧基,C.sub.1-4烷基磺酰基,C.sub.1-4烷基磺酸基,N(R.sup.5).sub.2,NHCOR.sup.5和SR.sup.5中选择的基团取代; R.sup.2是R.sup.6或--CH.dbd.CH--R.sup.6,当R.sup.1是COOR.sup.5,CONHR.sup.5,氰基或5-四唑基时,或当R.sup.1是R.sup.6时,R.sup.2是--CH.dbd.CH--R.sup.6; R.sup.3是氢,C.sub.1-6烷基,卤素,羟基或--OCH.sub.2R.sup.6; R.sup.4是氢,C.sub.1-6烷基或卤素;以及其盐。这些化合物具有药物特性,特别是在治疗哮喘等即时超敏反应病症方面有用。